An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 20 (1) , 4-9
Abstract
Seborrheic dermatitis (SD) is a chronic inflammatory disorder that mainly affects the seborrheic region. While ketoconazole is often used, pimecrolimus has been used successfully in SD. To compare the efficacy and tolerability of pimecrolimus in comparison with ketoconazole in the treatment of SD. A total of 48 patients with SD were included in the study. Patients were randomized into two groups: 23 and 25 patients in the pimecrolimus and ketoconazole groups, respectively. Clinical measures were assessed by erythema, scaling and infiltration, which were evaluated using a four-point scale (0 to 3) at 2, 6, and 12 weeks. Of these 48 patients, 38 completed the study (18 and 20 patients in the pimecrolimus and ketoconazole groups, respectively). The mean percentage decrease in clinical severity scores from baseline to the last follow-up period was 86.2% and 86.1% in the pimecrolimus and ketoconazole groups, respectively. Both pimecrolimus and ketoconazole were effective in SD. Differences between the two groups were not statistically significant. Side effects were observed more frequently with pimecrolimus than with ketoconazole and this difference was statistically significant. Our study showed that pimecrolimus had a comparable efficacy profile with that of ketoconazole, but side effects appeared more frequently in the pimecrolimus group than in the ketoconazole group.Keywords
This publication has 19 references indexed in Scilit:
- Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitisJournal of the American Academy of Dermatology, 2007
- Treatment of Facial Seborrheic Dermatitis with Pimecrolimus Cream 1%: An Open-Label Clinical Study in Korean PatientsJournal of Korean Medical Science, 2007
- Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double‐blind studyJournal of the European Academy of Dermatology and Venereology, 2006
- Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentationJournal of the American Academy of Dermatology, 2006
- Pimecrolimus in dermatology: atopic dermatitis and beyondInternational Journal Of Clinical Practice, 2005
- Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trialBritish Journal of Dermatology, 2004
- Etiology and Management of Seborrheic DermatitisDermatology, 2004
- Antimycotics: Why Are They Effective in the Treatment of Seborrheic Dermatitis?Dermatology, 2004
- Seborrheic dermatitisJournal of the European Academy of Dermatology and Venereology, 2003
- Kefoconazofe 2% Emulsion in the Treatment of Seborrheic DermatitisInternational Journal of Dermatology, 1991